Mecure's Strategic Move in Nigeria's Antibiotic Market Leads to Revenue Surge

Mecure, a Lagos-based pharmaceutical company, seized the opportunity created by GSK's departure from Nigeria's antibiotic market. With the launch of local manufacturing of amoxicillin clavulanate, Mecure's revenue skyrocketed, with a 118% increase to N37.3 billion in the first half of 2025.

The company's profit also surged to N2.7 billion in the same period. This strategic move reshaped Mecure's financial trajectory, making antibiotics a significant revenue driver alongside its diclofenac product.

The stock market responded positively to Mecure's performance, with its share price soaring by nearly 860% since its debut in 2023.